These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 10029385

  • 41. Mesalazine-induced lupus.
    Timsit MA, Anglicheau D, Lioté F, Marteau P, Dryll A.
    Rev Rhum Engl Ed; 1997 Oct; 64(10):586-8. PubMed ID: 9385697
    [Abstract] [Full Text] [Related]

  • 42. [Salicylates in the treatment of Crohn disease].
    Mangiarotti R, Prantera C.
    Ann Ital Chir; 1994 Oct; 65(3):279-81. PubMed ID: 7887577
    [No Abstract] [Full Text] [Related]

  • 43. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E, International Budesonide-Mesalazine Study Group.
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [Abstract] [Full Text] [Related]

  • 44. You're the flight surgeon. Crohn's disease.
    Hartwich SA.
    Aviat Space Environ Med; 2004 Aug; 75(8):716-7. PubMed ID: 15328792
    [No Abstract] [Full Text] [Related]

  • 45. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D.
    Harefuah; 1999 Jun 15; 136(12):943-5. PubMed ID: 10955155
    [No Abstract] [Full Text] [Related]

  • 46. Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease.
    Amankonah TD, Strom CB, Vierling JM, Petrovic LM.
    Am J Gastroenterol; 2001 Aug 15; 96(8):2520-2. PubMed ID: 11513216
    [No Abstract] [Full Text] [Related]

  • 47. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.
    Feagan BG.
    Clin Gastroenterol Hepatol; 2004 May 15; 2(5):376-8. PubMed ID: 15118974
    [No Abstract] [Full Text] [Related]

  • 48. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery.
    Doherty G, Moss AC.
    Am J Gastroenterol; 2012 Mar 15; 107(3):487; author reply 487-8. PubMed ID: 22388032
    [No Abstract] [Full Text] [Related]

  • 49. Mesalamine may be preferable to sulfasalazine in dermatologic therapeutics.
    Burkhart CG.
    Int J Dermatol; 2006 Jun 15; 45(6):779-80; author reply 780. PubMed ID: 16796652
    [No Abstract] [Full Text] [Related]

  • 50. Severe exudative ascites as an initial presentation of Crohn's disease.
    Tekin F, Vatansever S, Ozütemiz O, Musoğlu A, Ilter T.
    Turk J Gastroenterol; 2005 Sep 15; 16(3):171-3. PubMed ID: 16245232
    [Abstract] [Full Text] [Related]

  • 51. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A, Griga T, May B.
    Hepatogastroenterology; 1999 Sep 15; 46(30):3124-35. PubMed ID: 10626173
    [Abstract] [Full Text] [Related]

  • 52. [Mesalazine is effective in Crohn disease].
    Quartarolo JP.
    Ugeskr Laeger; 2005 Apr 18; 167(16):1767. PubMed ID: 15898611
    [No Abstract] [Full Text] [Related]

  • 53. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
    Kamm MA.
    Inflamm Bowel Dis; 2005 Jun 18; 11(6):616-7. PubMed ID: 15905712
    [Abstract] [Full Text] [Related]

  • 54. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS, Zlatanic J, Korelitz BI, Gleim GW.
    Am J Gastroenterol; 1999 Nov 18; 94(11):3254-7. PubMed ID: 10566725
    [Abstract] [Full Text] [Related]

  • 55. Education and imaging. Gastrointestinal: gastric Crohn's disease.
    Tseng TC, Chang YT, Wong JM.
    J Gastroenterol Hepatol; 2007 Oct 18; 22(10):1690. PubMed ID: 17845696
    [No Abstract] [Full Text] [Related]

  • 56. Dermatofibroma in a patient with Crohn's disease: a novel clinical manifestation.
    Beyazit Y, Caner S, Kurt M, Kekilli M, Aydog G, Ibis M.
    J Crohns Colitis; 2010 Oct 18; 4(4):490-1. PubMed ID: 21122552
    [No Abstract] [Full Text] [Related]

  • 57. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB.
    Aliment Pharmacol Ther; 2004 Oct 18; 20 Suppl 4():60-5. PubMed ID: 15352896
    [Abstract] [Full Text] [Related]

  • 58. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaïche J, Mary JY.
    Gastroenterology; 1996 Mar 18; 110(3):688-93. PubMed ID: 8608877
    [Abstract] [Full Text] [Related]

  • 59. Aminosalicylates and Elderly-onset Colonic Crohn's Disease-More Than Meets the Eye?
    Limdi JK.
    J Crohns Colitis; 2017 Aug 01; 11(8):1022. PubMed ID: 28333225
    [No Abstract] [Full Text] [Related]

  • 60. Mesalamine maintenance therapy for Crohn's disease.
    Feagan BG, McDonald JW.
    Gastroenterology; 2001 Feb 01; 120(2):585-6. PubMed ID: 11271451
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.